A primer probe combination, product and application thereof for detecting alzheimer's disease

By designing primer-probe combinations and the J-STAR technology platform, the problems of high invasiveness and low sensitivity in existing Alzheimer's disease detection methods have been solved, achieving high sensitivity and high specificity in early diagnosis and providing a reliable detection method for Alzheimer's disease.

CN122081486BActive Publication Date: 2026-07-28SHANGHAI JUNOVA BIOTECH CO LTD
2 Cites 0 Cited by

Patent Information

Application Number
CN202610534129.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2026-04-22
Publication Date
2026-07-28
Estimated Expiration
2046-04-22

AI Technical Summary

Technical Problem

Existing Alzheimer's disease detection methods suffer from problems such as high invasiveness, low sensitivity, and insufficient accuracy, making it difficult to achieve early, non-invasive, and efficient diagnosis.

Method used

A primer-probe combo was designed, including primer pairs and probes for detecting gene mutation sites and methylation sites. Fluorescent labeling and quenching groups were used in conjunction with the J-STAR technology platform for fluorescence amplification detection to construct an Alzheimer's disease risk assessment model.

Benefits of technology

It achieves low-invasiveness, low-cost, high-sensitivity, and high-specificity Alzheimer's disease detection, with a detection sensitivity of 88.89% and a specificity of 95.74%, enabling early detection of the disease and providing reliable diagnostic evidence.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present application relates to the technical field of gene detection, in particular to a primer probe combination for detecting Alzheimer's disease, a product and application thereof. The primer probe combination and kit provided by the present application can simultaneously detect Alzheimer's disease gene mutation and methylation, can effectively distinguish Alzheimer's disease patients from non-Alzheimer's disease subjects, realize low-invasive, low-cost, high-sensitivity, high-specificity detection of Alzheimer's disease, the total sensitivity of the blood sample for detecting Alzheimer's disease can reach 88.89%, the specificity of the blood sample for detecting non-Alzheimer's disease can reach 95.74%, the detection probability of false negative results can be reduced, and the detection accuracy is high.
Need to check novelty before this filing date? Find Prior Art